- Home
- GLPG vs KEN Comparison
GLPG vs KEN Comparison
Compare GLPG & KEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- KEN
- Stock Information
- Founded
- GLPG 1999
- KEN 2014
- Country
- GLPG Belgium
- KEN Singapore
- Employees
- GLPG N/A
- KEN N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- KEN Electric Utilities: Central
- Sector
- GLPG Health Care
- KEN Utilities
- Exchange
- GLPG Nasdaq
- KEN Nasdaq
- Market Cap
- GLPG 2.0B
- KEN 2.2B
- IPO Year
- GLPG 2005
- KEN N/A
- Fundamental
- Price
- GLPG $33.01
- KEN $47.74
- Analyst Decision
- GLPG Sell
- KEN
- Analyst Count
- GLPG 4
- KEN 0
- Target Price
- GLPG $25.33
- KEN N/A
- AVG Volume (30 Days)
- GLPG 372.1K
- KEN 19.2K
- Earning Date
- GLPG 07-23-2025
- KEN 09-08-2025
- Dividend Yield
- GLPG N/A
- KEN 10.00%
- EPS Growth
- GLPG N/A
- KEN N/A
- EPS
- GLPG N/A
- KEN 11.35
- Revenue
- GLPG $323,674,692.00
- KEN $760,304,000.00
- Revenue This Year
- GLPG $0.78
- KEN N/A
- Revenue Next Year
- GLPG N/A
- KEN N/A
- P/E Ratio
- GLPG N/A
- KEN $4.17
- Revenue Growth
- GLPG 5.43
- KEN 5.78
- 52 Week Low
- GLPG $22.36
- KEN $23.31
- 52 Week High
- GLPG $33.86
- KEN $49.99
- Technical
- Relative Strength Index (RSI)
- GLPG 67.37
- KEN 67.98
- Support Level
- GLPG $31.98
- KEN $47.82
- Resistance Level
- GLPG $33.66
- KEN $49.00
- Average True Range (ATR)
- GLPG 0.85
- KEN 0.72
- MACD
- GLPG 0.17
- KEN -0.18
- Stochastic Oscillator
- GLPG 88.39
- KEN 64.42
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About KEN Kenon Holdings Ltd.
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.